Organon & Co. (FRA:7XP)

Market Cap	3.02B +43.1%
Revenue (ttm)	5.35B -2.1%
Net Income	213.36M -67.2%
EPS	0.82 -67.2%
Shares Out	n/a
PE Ratio	14.14
Forward PE	3.95
Dividend	0.07 (0.60%)
Ex-Dividend Date	May 11, 2026

Volume	n/a
Open	11.39
Previous Close	11.49
Day's Range	11.39 - 11.54
52-Week Range	4.95 - 11.59
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 6, 2026

About Organon & Co.

Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women’s health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote develo...

• Industry: Pharmaceutical Preparations
• Founded: 1923
• Employees: 10,000
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 7XP

Financial Performance

In 2025, Organon & Co.'s revenue was $6.22 billion, a decrease of -2.92% compared to the previous year's $6.40 billion. Earnings were $187.00 million, a decrease of -78.36%.

Financial numbers in USD